Matching articles for "evolucumab"
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • February 11, 2019; (Issue 1565)
Cholesterol management guidelines from the American
College of Cardiology/American Heart Association Task
Force have recently been published. See Table 1 for a
brief summary of their...
Cholesterol management guidelines from the American
College of Cardiology/American Heart Association Task
Force have recently been published. See Table 1 for a
brief summary of their recommendations.
Reduction of Cardiovascular Risk with Evolocumab (Repatha)
The Medical Letter on Drugs and Therapeutics • April 24, 2017; (Issue 1519)
The results of the recently published FOURIER trial
have shown a reduction in cardiovascular events with
addition of the PCSK9 inhibitor evolocumab (Repatha)
to statin therapy in patients with...
The results of the recently published FOURIER trial
have shown a reduction in cardiovascular events with
addition of the PCSK9 inhibitor evolocumab (Repatha)
to statin therapy in patients with atherosclerotic
cardiovascular disease (ASCVD).
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • October 24, 2016; (Issue 1506)
Lipid-lowering drugs should be taken indefinitely;
when they are stopped, plasma lipoproteins return to
pretreatment levels. HMG-CoA reductase inhibitors
(statins) remain the drugs of choice for treatment...
Lipid-lowering drugs should be taken indefinitely;
when they are stopped, plasma lipoproteins return to
pretreatment levels. HMG-CoA reductase inhibitors
(statins) remain the drugs of choice for treatment of
most patients who require lipid-lowering therapy.
Alirocumab (Praluent) to Lower LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • August 17, 2015; (Issue 1475)
The FDA has approved the subcutaneously injected
PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor alirocumab (Praluent – Sanofi/Regeneron)
as an adjunct to diet and maximally...
The FDA has approved the subcutaneously injected
PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor alirocumab (Praluent – Sanofi/Regeneron)
as an adjunct to diet and maximally tolerated
statin therapy for adults with heterozygous familial
hypercholesterolemia (HeFH) or clinical atherosclerotic
cardiovascular disease who require additional lowering
of LDL-cholesterol (LDL-C). It was not approved for
general use in statin-intolerant patients. Alirocumab
is the first PCSK9 inhibitor to be approved in the US.
Evolocumab (Repatha – Amgen), another PCSK9
inhibitor, was recently approved in Europe and has been
recommended for approval for the same indications in
the US by an FDA Advisory Committee.